Search - tctmd.com

Displaying 181 - 200 of 584

Sort: Relevancy | Date

News Conference News AHA 2022

Partial Oral Antibiotic Regimen for Endocarditis Effective in Real World

Michael O'Riordan

November 10, 2022

News Conference News AHA 2022

Endothelin Receptor Antagonist Effective in Resistant Hypertension: PRECISION

Michael O'Riordan

November 09, 2022

News Conference News AHA 2022

Big Drops in Blood Pressure With Baxdrostat: BrigHTN Phase II Study

Michael O'Riordan

November 07, 2022

News Conference News AHA 2022

Common ‘Heart’ Supplements Can’t Beat Statins: SPORT

Michael O'Riordan

November 06, 2022

News Conference News AHA 2022

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

Michael O'Riordan

November 06, 2022

News Conference News AHA 2022

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

Michael O'Riordan

November 05, 2022

News Conference News AHA 2022

High-Sensitivity Troponin Testing on the Rise in the US but Still Limited

Michael O'Riordan

November 04, 2022

News Daily News

New Biomarker-Based Risk Score Performs Well in ACS

Michael O'Riordan

October 25, 2022

News Daily News

Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest

Michael O'Riordan

October 20, 2022

SPRINT Turns Sluggish: Mortality Benefits Vanish Once Normal Care Resumes

News Daily News

SPRINT Turns Sluggish: Mortality Benefits Vanish Once Normal BP Care Resumes

Michael O'Riordan

October 18, 2022

GDMT With ARNI Lessens MR, Perhaps Obviating Need for Interventions

News Conference News HFSA 2022

GDMT With ARNI Linked to Less MR, May Obviate Need for Interventions

Michael O'Riordan

October 04, 2022

News Daily News

mRNA Vaccine-Linked Myocarditis Resolves in Time, Without Clinical Events

Michael O'Riordan

September 26, 2022

News Daily News

COURAGE and ORBITA Had No Impact on Elective PCI Rates in UK

Michael O'Riordan

September 15, 2022

News Conference News ESC 2022

CV Care Around Noncardiac Surgery: New ESC Guidelines

Michael O'Riordan

September 07, 2022

News Conference News ESC 2022

Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE

Michael O'Riordan

August 31, 2022

News Conference News ESC 2022

Only Very Small Risk of Muscle Symptoms With Statins: CTT Collaboration

Michael O'Riordan

August 29, 2022

News Conference News ESC 2022

INVICTUS: More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF

Michael O'Riordan

August 28, 2022

News Conference News ESC 2022

Polypill Bests Usual Care in Patients With Recent MI: SECURE

Michael O'Riordan

August 26, 2022

News Daily News

After COVID-19, Unvaccinated at Risk for Long-term CVD Complications

Michael O'Riordan

August 16, 2022

News Features

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Michael O'Riordan

August 15, 2022

Advertisement

Partial Oral Antibiotic Regimen for Endocarditis Effective in Real World

Endothelin Receptor Antagonist Effective in Resistant Hypertension: PRECISION

Big Drops in Blood Pressure With Baxdrostat: BrigHTN Phase II Study

Common ‘Heart’ Supplements Can’t Beat Statins: SPORT

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

High-Sensitivity Troponin Testing on the Rise in the US but Still Limited

New Biomarker-Based Risk Score Performs Well in ACS

Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest

SPRINT Turns Sluggish: Mortality Benefits Vanish Once Normal BP Care Resumes

GDMT With ARNI Linked to Less MR, May Obviate Need for Interventions

mRNA Vaccine-Linked Myocarditis Resolves in Time, Without Clinical Events

COURAGE and ORBITA Had No Impact on Elective PCI Rates in UK

CV Care Around Noncardiac Surgery: New ESC Guidelines

Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE

Only Very Small Risk of Muscle Symptoms With Statins: CTT Collaboration

INVICTUS: More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF

Polypill Bests Usual Care in Patients With Recent MI: SECURE

After COVID-19, Unvaccinated at Risk for Long-term CVD Complications

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content